INMB
Price
$2.53
Change
+$0.17 (+7.20%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
68.92M
27 days until earnings call
RXRX
Price
$5.27
Change
+$0.06 (+1.15%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
2.14B
39 days until earnings call
Interact to see
Advertisement

INMB vs RXRX

Header iconINMB vs RXRX Comparison
Open Charts INMB vs RXRXBanner chart's image
INmune Bio
Price$2.53
Change+$0.17 (+7.20%)
Volume$77.52K
Capitalization68.92M
Recursion Pharmaceuticals
Price$5.27
Change+$0.06 (+1.15%)
Volume$265.47K
Capitalization2.14B
INMB vs RXRX Comparison Chart in %
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. RXRX commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (INMB: $2.53 vs. RXRX: $5.27)
Brand notoriety: INMB and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 156% vs. RXRX: 65%
Market capitalization -- INMB: $68.92M vs. RXRX: $2.14B
INMB [@Biotechnology] is valued at $68.92M. RXRX’s [@Biotechnology] market capitalization is $2.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • INMB’s TA Score: 5 bullish, 5 bearish.
  • RXRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -59.71% price change this week, while RXRX (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

INMB is expected to report earnings on Jul 30, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.14B) has a higher market cap than INMB($68.9M). RXRX YTD gains are higher at: -22.041 vs. INMB (-45.824). INMB has higher annual earnings (EBITDA): -41.52M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. INMB (19.3M). INMB has less debt than RXRX: INMB (347K) vs RXRX (92.9M). RXRX has higher revenues than INMB: RXRX (59.8M) vs INMB (50K).
INMBRXRXINMB / RXRX
Capitalization68.9M2.14B3%
EBITDA-41.52M-524.77M8%
Gain YTD-45.824-22.041208%
P/E RatioN/AN/A-
Revenue50K59.8M0%
Total Cash19.3M500M4%
Total Debt347K92.9M0%
FUNDAMENTALS RATINGS
INMB: Fundamental Ratings
INMB
OUTLOOK RATING
1..100
1
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
98
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INMBRXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPTHF0.120.01
+8.93%
OPTIMI HEALTH CORP.
CNLTL31.201.00
+3.31%
Connecticut Light & Power Co. (The)
DOCMF1.060.01
+0.62%
DR MARTENS PLC
RMSYF25.18N/A
N/A
Ramsay Health Care Ltd.
SYZLF6.16-0.04
-0.65%
Sylogist Ltd.

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UBX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
+7.20%
UBX - INMB
53%
Loosely correlated
-1.71%
ABCL - INMB
47%
Loosely correlated
+1.33%
BDTX - INMB
42%
Loosely correlated
-0.77%
ORMP - INMB
38%
Loosely correlated
+0.93%
RXRX - INMB
38%
Loosely correlated
+1.15%
More